Atea Pharmaceuticals Inc (AVIR NASDAQ) stock market data APIs
$4.3501
0.01(0.2%)
as of February 13, 2026
Try our APIs with
free plan!
Atea Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Prev. Close
4.3501
Open
4.3564
High
4.3564
Low
4.2231
52 wk Range
2.455-4.5
Market Cap
337 M
Shares Outstanding
78 127 K
Revenue
192 M
EPS
-0.53
Beta
0.231
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Atea Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Atea Pharmaceuticals Inc data using free add-ons & libraries
Get Atea Pharmaceuticals Inc Fundamental Data
Atea Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 192 M
- EBITDA: -158 774 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.42
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Atea Pharmaceuticals Inc News
New
CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround
On February 2, BML Capital Management, LLC disclosed a new position in CarMax(NYSE:KMX), acquiring 155,000 shares in an estimated $5.99 million trade based on quarterly average pricing. What happened...
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
On February 2, BML Capital Management disclosed in a Securities and Exchange Commission filing that it sold out of Alumis(NASDAQ:ALMS), liquidating 1,210,415 shares in an estimated $4.83 million trade...
Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals, Inc. Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-...
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral ant...
Get Atea Pharmaceuticals Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
